$2.1 Billion is the total value of Redmile Group, LLC's 68 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -2,912,228 | -100.0% | -0.09% | – |
| GRFS | Exit | GRIFOLS S Asp adr rep b nvt | $0 | – | -600,684 | -100.0% | -0.21% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -1,698,626 | -100.0% | -0.21% | – |
| Exit | STEVANATO GROUP S P A | $0 | – | -218,169 | -100.0% | -0.27% | – | |
| Exit | ACELYRIN INC | $0 | – | -364,493 | -100.0% | -0.29% | – | |
| MDVL | Exit | MEDAVAIL HOLDINGS INC | $0 | – | -34,604,516 | -100.0% | -0.33% | – |
| IQV | Exit | IQVIA HLDGS INC | $0 | – | -94,409 | -100.0% | -0.81% | – |
| ZBH | Exit | ZIMMER BIOMET HOLDINGS INC | $0 | – | -151,372 | -100.0% | -0.85% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLC | $0 | – | -341,882 | -100.0% | -1.63% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -489,208 | -100.0% | -1.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.